Werewolf Therapeutics, Inc. Share Price & Technical Analysis
HOWL · $0.46 (+4.55%)
Healthcare / Biotechnology
$0.46
+4.55%
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies throug…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-29% return in May, 17% avg return in past 3 year May month.
-5% return in 2026, 1% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 17% | -14% | 33% | -12% | -29% | – | – | – | – | – | – | – | -5% |
| 25 | -13% | -8% | -17% | -10% | 33% | -8% | 9% | 8% | 54% | -35% | -23% | -40% | -49% |
| 24 | 18% | 44% | -7% | -5% | -16% | -49% | -12% | -4% | -5% | 24% | -20% | -25% | -57% |
| 23 | 90% | -27% | -10% | -4% | 33% | -6% | -10% | 0% | -25% | 14% | -7% | 63% | 109% |
| 22 | -23% | -21% | -38% | 0% | -14% | 5% | 12% | 6% | -10% | -33% | -38% | 11% | -142% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$31.47M
P/E ratio
—
52W high
$2.38
52W low
$0.40
Volume
7,97,898
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Werewolf Therapeutics, Inc. share price today?
- Werewolf Therapeutics, Inc. (HOWL) last traded around $0.46 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does HOWL have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for HOWL. Download the app for real-time alerts.
- How can I analyze Werewolf Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.